Vernakalant - Correvio Pharma

Drug Profile

Vernakalant - Correvio Pharma

Alternative Names: Brinavess; Kynapid; MK-6621; RSD-1235; vernakalant (IV); vernakalant (oral); Vernakalant-hydrochloride

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardiome Pharma
  • Developer Algorithm; Aspen Pharmacare; ATCO Laboratories; Correvio Pharma
  • Class Anisoles; Antiarrhythmics; Cyclohexanes; Pyrrolidines; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Atrial fibrillation

Most Recent Events

  • 11 Jun 2018 Correvio expects a pre-NDA meeting with the US FDA for vernakalant's NDA resubmission discussion in the fourth quarter of 2018
  • 17 May 2018 Eddingpharm initiates enrolment in the phase III trial for Atrial fibrillation in China (IV)
  • 15 May 2018 Cipher Pharmaceuticals acquires Vernakalant from Correvio Pharma in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top